The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Until today this year the stock’s price performance recorded a decrease of -28.48%. However, over the last six months, the performance has been weaker by 13.25%. The price of NAMS decreased -9.32% over the last 30 days. And in the last five days, it has fallen by -21.49%.
NewAmsterdam Pharma Company NV ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $27.29 on 12/11/24, while the lowest value for the same period was recorded at $15.19 on 09/25/24.
52-week price history of NAMS Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. NewAmsterdam Pharma Company NV’s current trading price is -32.65% away from its 52-week high, while its distance from the 52-week low is 21.00%. The stock’s price range during this time has been between $15.19 and $27.29. The trading volume for the Healthcare sector company’s shares reached about 2.59 million for the day, which was higher than the average daily volume of 0.89 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
NewAmsterdam Pharma Company NV (NAMS) has experienced a quarterly decline of -28.92% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.02B and boasts a workforce of 68 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 22.52, with a change in price of +0.35. Similarly, NewAmsterdam Pharma Company NV recorded 975,063 in trading volume during the last 100 days, posting a change of +1.94%.
NAMS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for NAMS stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
NAMS Stock Stochastic Average
Today’s raw stochastic average for NewAmsterdam Pharma Company NV over the last 50 days is 16.37%.This indicates a increase from the raw stochastic average of the past 20 days, which was 5.98%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 24.71% and 41.05%, respectively.
